| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | NU-7441 | GDSC1000 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | ETP-46464 | CTRPv2 | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | BRD-K29313308 | CTRPv2 | pan-cancer | AAC | -0.0055 | 0.9 |